430 East 29th Street
New York , NY 10016
New York , NY 10016
News
-
Karuna Therapeutics soared 47.4% to $317.22 after Bristol Myers agreed to pay $330 per share, or $14 billion, to acquire the maker of the schizophrenia drug KarXT.
The U.S. Food and Drug Administration has accepted KarXT for a review.
Bristol-Myers declined 1.7% to $50.36.
Dec 22, 2023 -
Bristol-Myers Squibb dropped 5.7% to $53.40 after the company reported quarterly earnings.
The pharmaceutical company said sales of its popular blood cancer drug, Revlimid, were down because of rising competition from generic drugs.
Revenue in the third quarter declined 2% to $10.96 billion from $11.2 billion, net income rose to $1.9 billion from $1.2 billion, and diluted earnings per share advanced to 93 cents from 75 cents a year ago.
Revlimid worldwide revenues fell 41% from a year ago to $1.4 billion, primarily due to generic competition and an increas More
Oct 26, 2023
Executive/
Director
Links
Price
- Last Close
-
$ 56.57
$ -0.25 -0.44 %
Jan 3, 2025
- 52-Week High/Low
- $62.01 - $40.13
- YTD
- -0%
- Trading Volume
- 337,218
- Market Cap Full
- $ 115.1B
- Shares Outstanding
-
2034.8M
Oct 20, 2023
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | -6.6% | -6.3% | 3.9% | -8.3% | -5% | 2.8% | 17.1% | -3.7% | 5.3% | -0% |
| Q2 | 15.8% | 3.2% | -10.2% | -3.2% | 4% | 4.9% | 5.4% | -7.8% | -21.6% | - |
| Q3 | -26.7% | 15.2% | 13.3% | 10.7% | 8% | -10.8% | -8.4% | -9.2% | 4.8% | - |
| Q4 | 9.1% | -4.5% | -15.8% | 25.1% | 1.9% | 5.4% | 2% | -11.4% | 3.5% | - |
| J | F | M | A | M | J | J | A | S | O | N | D | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0% | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | -4.8% | 3.9% | 6.5% | -9.4% | -16% | 1% | 14.3% | 4.8% | - | - | - | -4.5% |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19% | -13% | 8% | -13% | 24% | -4% | 1% | 15% | -29% | 10% | -0% |
Earnings
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Q1 | 0.74 | 0.84 | 0.91 | 1.04 | -0.34 | 0.89 | 0.59 | 1.07 |
| Q2 | 0.69 | 0.74 | 0.23 | 0.87 | -0.04 | 0.47 | 0.66 | 0.99 |
| Q3 | 0.77 | 0.75 | 1.16 | 0.83 | 0.82 | 0.69 | 0.75 | 0.93 |
| Q4 | 0.63 | 0.68 | 0.71 | -0.55 | -4.43 | 1.07 | 0.95 | - |
| A | 2.8 | 3 | 3 | 2 | -4 | 3.1 | 3 | 2.99 |
Annual Returns
52 Week
High/Low
Annual
Earnings
Chart
Trading Volume
Dividend +
Dividend +
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Q1 | 0.45 | 0.49 | 0.54 | 0.57 | 0.60 | 0.62 |
| Q2 | 0.45 | 0.49 | 0.54 | 0.57 | 0.60 | - |
| Q3 | 0.45 | 0.49 | 0.54 | 0.57 | 0.60 | - |
| Q4 | 0.45 | 0.49 | 0.54 | 0.57 | 0.60 | - |
| A | 1.8 | 1.96 | 2.16 | 2.28 | 2.4 | 0.62 |
Outstanding Shares
(In Millions) +
Jan 16, 2024
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Mar | 1634.5 | 1635.7 | 2262.7 | 2232.8 | 2129.1 | 2098.8 |
| Jun | 1631.9 | 1635.8 | 2253.9 | 2222.1 | - | 2100.8 |
| Sep | 1632.2 | 1629.3 | 2259.8 | 2219.6 | 2135.3 | 2089.1 |
| Dec | - | - | - | - | 2126.2 | 2034.8 |
SEC Filings
Financial Ratios
| 2022 | 2021 | 2020 | 2019 | 2018 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Management | ||||||||||||||||||
| Inventory / Stock Turnover | 4.3 | 4.7 | 5.7 | 1.9 | 5.5 | |||||||||||||
| Fixed Asset Turnover | 4.1 | 4 | 3.2 | 1.9 | 2.6 | |||||||||||||
| Total Asset Turnover | 0.5 | 0.4 | 0.4 | 0.2 | 0.6 | |||||||||||||
| Leverage | ||||||||||||||||||
| Debt Ratio | 1.3 | 1.2 | 1.6 | 1.5 | 0.3 | |||||||||||||
| Debt – Equity Ratio | 1.1 | 1.1 | 1.3 | 0.8 | 0.4 | |||||||||||||
| Interest Coverage | 5.6 | 7.3 | -3.2 | 3.2 | 5.7 | |||||||||||||
| Equity multiplier | 0.4 | 0.3 | 0.4 | 0.3 | 0.6 | |||||||||||||